Brexit and longer-term sector trends could boost UK pharma M&A/investment

20 July 2017

The pharmaceutical industry is one of the UK’s great success stories, writes Michael Jewell, healthcare partner at Cavendish Corporate Finance, in an Expert View piece on how the sector could see an increase in deal-making as Brexit looms.

Overall, the life sciences sector that generates more than £30 billion ($39 billion) a year for the UK economy, supports some 500,000 jobs and has enjoyed rapid growth over the past decade.

The pharma sector accounts for around 10% of GDP and also generates a £3 billion trade surplus. This growth has been achieved partly through a close relationship with the European Union (EU), which now must be revised as part of the process of leaving the trading bloc. However, the UK’s upcoming EU departure coupled with such sector trends as increasing patent expirations and declining returns on research and development (R&D) could help boost mergers and acquisitions (M&A) and investment in the UK pharma sector.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK